Immunity, Inflammation and Disease

Cover image for Vol. 4 Issue 4

Early View (Online Version of Record published before inclusion in an issue)

Editor-in-Chief Dr. Marc Veldhoen, Institute for Molecular Medicine, University of Lisbon, Portugal

Online ISSN: 2050-4527


  1. 1
  1. Original Research

    1. You have full text access to this OnlineOpen article
      Transient Treg depletion enhances therapeutic anti-cancer vaccination

      Scott A. Fisher, Wayne J. Aston, Jonathan Chee, Andrea Khong, Amanda L. Cleaver, Jessica N. Solin, Shaokang Ma, W. Joost Lesterhuis, Ian Dick, Robert A. Holt, Jenette Creaney, Louis Boon, Bruce Robinson and Richard A. Lake

      Version of Record online: 21 NOV 2016 | DOI: 10.1002/iid3.136

      Thumbnail image of graphical abstract

      Regulatory T cells (Treg) play an important role in suppressing anti- immunity. Given the recent advances in the use of immune based cancer therapies, the role of Treg suppression in limiting anti- immunity is currently generating great interest. In this work, we show that the BALB/c FoxP3.dtr transgenic mouse is an ideal model to explore the full therapeutic potential of Treg depletion. We show that DTX-mediated Treg depletion is transient and dose-dependent; it can lead to strong anti-tumor immunity and complete tumor regression of several different solid tumors. Importantly, we show that partial Treg depletion improves the efficacy of tumor specific vaccine immunotherapy.


  1. 1